Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Helsinn’s Family-Business Approach Goes Global In Cancer Care

Executive Summary

Privately-owned Swiss firm preparing for its first solo launch in the US by doubling its sales force.

You may also be interested in...



Deal Watch: Opportunity Knocks For Partnerships In Asia

ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.

Helsinn Family Business Establishes $50m Start-Up Investment Fund

The family-owned Swiss firm Helsinn has taken its pastoral business approach into the incubation of promising biotech startups by setting up a $50m fund for injecting seed capital into promising prospects.

Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio

Helsinn will help MEI Pharma advance its HDAC inhibitor pracinostat into Phase III development via a partnership worth up to $464m.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel